Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (971-980 of 993) with videos related to

Pageof 100
Sort By:
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 9, 2019
Controversial issues in the management of patients with advanced prostate cancer: Results from a Canadian consensus forumFred Saad, Christina Canil, Antonio Finelli, et al.
The Lancet. Oncology|January 21, 2015
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyCharles J Ryan, Matthew R Smith, Karim Fizazi, et al.
The New England Journal of Medicine|June 3, 2014
Enzalutamide in metastatic prostate cancer before chemotherapyTomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, et al.
Journal for Immunotherapy of Cancer|August 17, 2022
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trialKarim Fizazi, Margitta Retz, Daniel P Petrylak, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 14, 2021
Results from a Canadian consensus forum of key controversial areas in the management of advanced prostate cancer: Recommendations for Canadian healthcare providersFred Saad, Sebastien J Hotte, Antonio Finelli, et al.
Cancer Letters|November 7, 2022
UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathwaysLouis Lacombe, Hélène Hovington, Hervé Brisson, et al.
The New England Journal of Medicine|May 27, 2011
Abiraterone and increased survival in metastatic prostate cancerJohann S de Bono, Christopher J Logothetis, Arturo Molina, et al.
Nature Communications|December 16, 2025
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancerSoumyajit Roy, Yilun Sun, Maha Hussain, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 8, 2022
The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray ResourceVéronique Ouellet, Andrew Erickson, , et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2025
Metformin Active Surveillance Trial in Low-Risk Prostate CancerNeil E Fleshner, Rui M Bernardino, Jonathan Izawa, et al.
Pageof 100

Showing results (971-980 of 993) with videos related to

Sort By:
Pageof 100
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 9, 2019
Controversial issues in the management of patients with advanced prostate cancer: Results from a Canadian consensus forumFred Saad, Christina Canil, Antonio Finelli, et al.
The Lancet. Oncology|January 21, 2015
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyCharles J Ryan, Matthew R Smith, Karim Fizazi, et al.
The New England Journal of Medicine|June 3, 2014
Enzalutamide in metastatic prostate cancer before chemotherapyTomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, et al.
Journal for Immunotherapy of Cancer|August 17, 2022
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trialKarim Fizazi, Margitta Retz, Daniel P Petrylak, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 14, 2021
Results from a Canadian consensus forum of key controversial areas in the management of advanced prostate cancer: Recommendations for Canadian healthcare providersFred Saad, Sebastien J Hotte, Antonio Finelli, et al.
Cancer Letters|November 7, 2022
UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathwaysLouis Lacombe, Hélène Hovington, Hervé Brisson, et al.
The New England Journal of Medicine|May 27, 2011
Abiraterone and increased survival in metastatic prostate cancerJohann S de Bono, Christopher J Logothetis, Arturo Molina, et al.
Nature Communications|December 16, 2025
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancerSoumyajit Roy, Yilun Sun, Maha Hussain, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 8, 2022
The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray ResourceVéronique Ouellet, Andrew Erickson, , et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2025
Metformin Active Surveillance Trial in Low-Risk Prostate CancerNeil E Fleshner, Rui M Bernardino, Jonathan Izawa, et al.
Pageof 100